Abstract
Recently, the administration of high-dose cyclophosphamide (Cy) after Tcell-replete haploidentical stem cell infusion has been reported to be feasible and effective. In the original study, bone marrow (BM) was used as the source of stem cells. Here, we retrospectively analyzed the use of BM versus peripheral blood stem cells (PBSCs) in a cohort of patients receiving haploidentical Tcell-replete transplantation after a nonmyeloablative conditioning regimen with postinfusion Cy. In the PBSC versus BM groups, the incidence of acute graft-versus-host disease (GVHD) was 33% versus 25%, respectively, and the incidence of chronic GVHD was 13% versus 13%, respectively. The median time to achieve a safe and unsupported absolute neutrophil and platelet count was 20 versus 21days and 27 versus 29days, respectively. The incidence of engraftment was also similar in the 2 cohorts. The 1-year nonrelapse mortality rate was 12% versus 22%, respectively (P=.96). Finally, nonsignificant differences in survival were observed. In conclusion, the use of PBSCs instead of BM after Tcell-replete haploidentical transplantation did not appear to be detrimental in terms of either GVHD or engraftment rate. PBSCs could be a valid alternative to BM after transplantation from a haploidentical donor using postinfusion Cy.
| Original language | English |
|---|---|
| Pages (from-to) | 724-729 |
| Number of pages | 6 |
| Journal | Biology of Blood and Marrow Transplantation |
| Volume | 20 |
| Issue number | 5 |
| DOIs | |
| Publication status | Published - 2014 |
Fingerprint
Keywords
- Haploidentical transplantation
- Postinfusion cyclophosphamide
- Stem cell sources
ASJC Scopus subject areas
- Transplantation
- Hematology
- Medicine(all)
Cite this
Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide. / Castagna, Luca; Crocchiolo, Roberto; Furst, Sabine; Bramanti, Stefania; El Cheikh, Jean; Sarina, Barbara; Granata, Angela; Mauro, Elisa; Faucher, Catherine; Mohty, Bilal; Harbi, Samia; Chabannon, Christian; Carlo-Stella, Carmelo; Santoro, Armando; Blaise, Didier.
In: Biology of Blood and Marrow Transplantation, Vol. 20, No. 5, 2014, p. 724-729.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Bone Marrow Compared with Peripheral Blood Stem Cells for Haploidentical Transplantation with a Nonmyeloablative Conditioning Regimen and Post-transplantation Cyclophosphamide
AU - Castagna, Luca
AU - Crocchiolo, Roberto
AU - Furst, Sabine
AU - Bramanti, Stefania
AU - El Cheikh, Jean
AU - Sarina, Barbara
AU - Granata, Angela
AU - Mauro, Elisa
AU - Faucher, Catherine
AU - Mohty, Bilal
AU - Harbi, Samia
AU - Chabannon, Christian
AU - Carlo-Stella, Carmelo
AU - Santoro, Armando
AU - Blaise, Didier
PY - 2014
Y1 - 2014
N2 - Recently, the administration of high-dose cyclophosphamide (Cy) after Tcell-replete haploidentical stem cell infusion has been reported to be feasible and effective. In the original study, bone marrow (BM) was used as the source of stem cells. Here, we retrospectively analyzed the use of BM versus peripheral blood stem cells (PBSCs) in a cohort of patients receiving haploidentical Tcell-replete transplantation after a nonmyeloablative conditioning regimen with postinfusion Cy. In the PBSC versus BM groups, the incidence of acute graft-versus-host disease (GVHD) was 33% versus 25%, respectively, and the incidence of chronic GVHD was 13% versus 13%, respectively. The median time to achieve a safe and unsupported absolute neutrophil and platelet count was 20 versus 21days and 27 versus 29days, respectively. The incidence of engraftment was also similar in the 2 cohorts. The 1-year nonrelapse mortality rate was 12% versus 22%, respectively (P=.96). Finally, nonsignificant differences in survival were observed. In conclusion, the use of PBSCs instead of BM after Tcell-replete haploidentical transplantation did not appear to be detrimental in terms of either GVHD or engraftment rate. PBSCs could be a valid alternative to BM after transplantation from a haploidentical donor using postinfusion Cy.
AB - Recently, the administration of high-dose cyclophosphamide (Cy) after Tcell-replete haploidentical stem cell infusion has been reported to be feasible and effective. In the original study, bone marrow (BM) was used as the source of stem cells. Here, we retrospectively analyzed the use of BM versus peripheral blood stem cells (PBSCs) in a cohort of patients receiving haploidentical Tcell-replete transplantation after a nonmyeloablative conditioning regimen with postinfusion Cy. In the PBSC versus BM groups, the incidence of acute graft-versus-host disease (GVHD) was 33% versus 25%, respectively, and the incidence of chronic GVHD was 13% versus 13%, respectively. The median time to achieve a safe and unsupported absolute neutrophil and platelet count was 20 versus 21days and 27 versus 29days, respectively. The incidence of engraftment was also similar in the 2 cohorts. The 1-year nonrelapse mortality rate was 12% versus 22%, respectively (P=.96). Finally, nonsignificant differences in survival were observed. In conclusion, the use of PBSCs instead of BM after Tcell-replete haploidentical transplantation did not appear to be detrimental in terms of either GVHD or engraftment rate. PBSCs could be a valid alternative to BM after transplantation from a haploidentical donor using postinfusion Cy.
KW - Haploidentical transplantation
KW - Postinfusion cyclophosphamide
KW - Stem cell sources
UR - http://www.scopus.com/inward/record.url?scp=84897957070&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84897957070&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2014.02.001
DO - 10.1016/j.bbmt.2014.02.001
M3 - Article
VL - 20
SP - 724
EP - 729
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
SN - 1083-8791
IS - 5
ER -